Con mittee on Energy and Commerce U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)

| Are you testifying on behalf of the Federal, or a State or local government entity? Are you testifying on behalf of an entity that is not a government entity? Are you testifying on behalf of an entity that is not a government entity? Other than yourself, please list which entity or entities you are representing: HUK Venture Parluers Network Venture Capital Association (NVCA) Please list any Federal grants or contracts (including subgrants or subcontraty you or the entity you represent have received on or after October 1, 2011: None If your answer to the question in item 3 in this form is "yes," please describe position or representational capacity with the entity or entities you are repredised. Account NUCA If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grants contracts (including subgrants or subcontracts) that were received by the enunder the question in item 4 on or after October 1, 2011, that exceed 10 percenter of the parent organization of the second se | 1. | Your Name: TERCH- DAGI MD MPH Dued Sc |
|--|----|---|
| 3. Are you testifying on behalf of an entity that is not a government entity? 4. Other than yourself, please list which entity or entities you are representing: Hum Venture Pavluevs, National Venture Capital Association (NVCA) 5. Please list any Federal grants or contracts (including subgrants or subcontray you or the entity you represent have received on or after October 1, 2011: None. 6. If your answer to the question in item 3 in this form is "yes," please describe position or representational capacity with the entity or entities you are represented on or after October 1, 2011: None. 7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are: not representing in your testimony? 8. If the answer to the question in item 3 is "yes," please list any Federal grants contracts (including subgrants or subcontracts) that were received by the enumber to question in item 3 is "yes," please list any Federal grants contracts (including subgrants or subcontracts) that were received by the enumber the question in item 4 on or after October 1, 2011, that exceed 10 percervenue of the entities in the year received, including the source and amount grant or contract to be listed: [ione] | 2. | Are you testifying on behalf of the Federal, or a State or local Yes No |
| 4. Other than yourself, please list which entity or entities you are representing: HUN Venture Parluers Network Venture Capital Association (NVCA) 5. Please list any Federal grants or contracts (including subgrants or subcontrative you or the entity you represent have received on or after October 1, 2011: None 6. If your answer to the question in item 3 in this form is "yes," please describe position or representational capacity with the entity or entities you are represent General Partners HUM Venture Partners MCMber NVCA 7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? 8. If the answer to the question in item 3 is "yes," please list any Federal grants contracts (including subgrants or subcontracts) that were received by the enunder the question in item 4 on or after October 1, 2011, that exceed 10 perceivenue of the entities in the year received, including the source and amount grant or contract to be listed: 1:0Ne | 3. | Are you testifying on behalf of an entity that is not a government (Yes) No |
| you or the entity you represent have received on or after October 1, 2011: None | | Other than yourself, please list which entity or entities you are representing: HUN VENTURE Parlners Network Venture (apital Association (NVCA) |
| position or representational capacity with the entity or entities you are represented for the partner for the partner for the partners for the partners for the partner for the partners for the parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? 8. If the answer to the question in item 3 is "yes," please list any Federal grants contracts (including subgrants or subcontracts) that were received by the en under the question in ite n 4 on or after October 1, 2011, that exceed 10 percerevenue of the entities in the year received, including the source and amount grant or contract to be listed: | | None |
| A report answer to the question in item 5 is 'yes,' us any of the entities' disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? 8. If the answer to the question in item 3 is "yes," please list any Federal grants contracts (including subgrants or subcontracts) that were received by the en under the question in ite n 4 on or after October 1, 2011, that exceed 10 perc revenue of the entities in the year received, including the source and amount grant or contract to be listed: [] one | 6. | |
| contracts (including subgrants or subcontracts) that were received by the en under the question in ite n 4 on or after October 1, 2011, that exceed 10 perc revenue of the entities in the year received, including the source and amount grant or contract to be listed: | 7. | disclosed in item 4 have parent organizations, subsidiaries, or |
| 9. Please attach your curriculum vitae to your completed disclosure form. | 8. | 5 |
| | 9. | Please attach your curriculum vitae to your completed disclosure form. |

Signature:

Date: March 18 2013

Teodoro Forcht Dagi

MD, MPH, DMedSc, MBA, FAANS, FACS, FCCM

Teodoro Forcht (Teo) Dagi is a general partner at HLM Venture Partners, a life sciences venture fund in Boston and San Francisco, Distinguished Scholar and Professor at the School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, Northern Ireland, and Visiting Professor at Harvard Medical School.

Teo received an AB Columbia, and an MD and MPH from Johns Hopkins. He trained in neurosurgery at the Massachusetts General Hospital and the Guy's, Maudsley and King's College Hospitals Neurosurgical Unit in London. He was appointed the Neuroresearch Foundation Fellow, and then the Joseph P. Kennedy, Jr., Fellow at Harvard University. Teo also received an MBA with distinction from Wharton and was awarded a DMedSc (*Honoris Causae*) from Queen's University for contributions to medicine and public service.

After completing his neurosurgical training, Teo worked in the Laboratory of Cerebral Metabolism at the NIH, and developed the skull base and functional neurosurgery programs at Georgetown. During his military service, he developed field resuscitation protocols, served as a flight surgeon and combat neurosurgeon, and organized the US revision of the NATO handbook of War Surgery. For his work in developing mobile ICU systems and other contributions to critical care in mass casualty settings, he was elected to Fellowship in the College of Critical Care Medicine, the first neurosurgeon so honoured. He was appointed medical consultant to the Office of Technology Assessment of the US Congress, then Special Assistant to the Secretary of the Administrative Conference of the United States and subsequently Special Assistant to the Assistant Secretary of Defence for Health Affairs and consultant to the FDA in neurological drugs and devices.

In 1997, Teo established a small venture capital fund to support early stage university-based biomedical spin-outs in the southeast, which ultimately yielded over \$4 billion in portfolio value. He was recruited to the Georgia Institute of Technology, where he developed the first curriculum in translational and biomedical science. He became an advisor to a number of universities looking to institute programs in translational medicine. At the invitation of the British Government, he chaired the International Advisory Panel for Biotechnology for Northern Ireland. He was appointed to the US-Israel Science and Technology Commission of the US Department of Commerce, and helped establish the Israel Life Sciences Association. Later he served as an advisor in new technology support and commercialization to the Director of the NIH and the Office of Biodefense Research Affairs of the Division of Microbiology and Infections disease of NIAID. He has also advised the governments of Denmark and Norway in biomedical ventures, as well as financial institutions such as the Royal Bank of Canada. He chaired the scientific advisory board for the pharmaceuticals section of Dupont, and has served on numerous other scientific advisory boards.

In 2002 Teo joined the faculty of the Harvard-MIT Program in Health Sciences and Technology, and in 2007 he assumed the chairmanship of the School of Medicine, Dentistry and Biomedical Sciences of Queen's University Belfast in Northern Ireland, helping to raise over £350 million in infrastructure support. In the wake of the Peace Process, the school is now one of the highest ranked in England, joining the Russell 20 after expanding by 40%, and winning coveted St. James Prize from Queen Elizabeth for biomedical research as part of the Queen's Jubilee Celebration of 2012.

Teo was named the Sir Thomas and Edith Dixon Medalist and lecturer for 2012. In 2013, he was named to Fellowship in the Royal College of Surgeons, Edinburgh *ad hominem*, one of the highest honors bestowed by the oldest surgical organization in the world.

Teo has been a director of both privately held and publicly traded corporations. He teaches at Harvard Business School as well as Harvard Medical School, and at the Venture Capital Institute of the Venture Capital Association. He was appointed to the Board of Directors of the Georgia Institute of Technology, the Alumni Board of Advisors to the Wharton School and later the Board of the Goergen Entrepreneurship Institute of the University of Pennsylvania.

He chaired the Georgia Neurosurgical Society, served as director of the American Association of Neurological Surgeons, chair of the AANS Ethics Committee and principle author of the AANS handbook of ethics. He now chairs the Committee on Perioperative Care for the American College of Surgeons, and serves as an officer and director of the Council on Surgical and Perioperative Safety and a director of the Anaesthesia Patient Safety Foundation.

Teo has authored or edited eight books and monographs, and over 200 chapters and articles. He is an editor of Neurosurgery, and the Journal of Clinical Ethics.

Teo lives in Newton, Massachusetts with his wife Linda, a paediatric ophthalmologist at Boston Children's Hospital, and has three children. A mountain climber, he participated as the physician to a National Geographic Everest expedition. He is also a sailor, skier, and published photographer.